Skip to main navigation
Skip to search
Skip to main content
Mayo Clinic Home
Home
Profiles
Departments/Divisions
Grants
Research output
Prizes
Search by expertise, name or affiliation
Eculizumab monotherapy for NMOSD: Data from PREVENT and its open-label extension
the PREVENT Study Group
Neurology
Neurology
Research output
:
Contribution to journal
›
Article
›
peer-review
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Eculizumab monotherapy for NMOSD: Data from PREVENT and its open-label extension'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Medicine & Life Sciences
eculizumab
100%
Immunoglobulin G
50%
Aquaporin 4
29%
Neuromyelitis Optica
29%
Secondary Prevention
21%
Immunosuppression
19%
Placebos
15%
Confidence Intervals
13%
Recurrence
12%